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ABSTRACT
Objective: The primary objective of this review article is to provide a coherent,
systematic synthesis of the literature on the management of suicidality in
schizophrenia that is relevant to the front-line clinician.
Method: Literature searches were conducted on MEDLINE (1996 to 2007) and
PubMed (1993 to 2007), using the key words “schizophrenia” and “suicide,” as well
as references from the resulting articles. I used my own clinical experience to create
fictional case examples to illustrate the applicability of the literature discussed in this
paper.
Results: Suicidality in schizophrenia is high, and early detection relies on the
appreciation and evaluation of the clinical manifestations of depression, despair, and
hopelessness, as well as on the nature and severity of the psychotic experience itself,
particularly in recent-onset patients with higher cognitive function and educational
background. Clinical management includes ensuring immediate safety, the use of
psychosocial techniques to address depression and psychosocial stressors, targeted
pharmacotherapy for depression and psychosis, and adequate discharge planning.
Clozapine is the only antipsychotic with good evidence for efficacy in decreasing
suicidal behaviour in schizophrenia.
Conclusions: The optimal management of suicidality in schizophrenia involves the
incorporation of traditional bedside clinical skills, selection of psychosocial modalities
based on individual needs, and selective pharmacotherapy directed primarily at
psychotic and depressive symptoms.
RÉSUMÉ
Objectif : L’objectif principal de cet article de synthèse est de procurer une synthèse
cohérente et systématique de la documentation sur la prise en charge de la suicidabilité
dans la schizophrénie qui soit utile au clinicien de première ligne.
Méthode : Des recherches documentaires ont été menées dans MEDLINE (1996 à
2007) et PubMed (1993 à 2007) à l’aide des mots clés « schizophrénie » et « suicide »,
ainsi que dans les bibliographies des articles trouvés. Je me suis servi de ma propre
expérience clinique pour créer des exemples de cas fictifs afin d’illustrer
l’applicabilité de la documentation présentée dans cet article.
Résultats : La suicidabilité est élevée dans la schizophrénie, et la détection précoce
repose sur l’appréciation et l’évaluation des manifestations cliniques de dépression, de
désespoir et d’impuissance, ainsi que sur la nature et la gravité de l’expérience
psychotique même, en particulier chez les patients où la maladie est apparue
récemment et qui ont une fonction cognitive élevée et une bonne instruction. La prise
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Schizophrenia is a devastating neuropsychiatric conditionoften striking in late adolescence to early adulthood, time
periods that are critical for psychological, interpersonal, and
vocational development. Indeed, managing patients in the
early years of their illness often entails addressing these key
areas through various forms of psychotherapeutic and voca-
tional interventions. The illness manifests with various com-
binations of positive, negative, and cognitive symptoms.
Even with successful treatment, full eradication of these
symptoms is not possible in most patients. Mortality in schizo-
phrenia patients is 2 to 3 times higher than that in the general
population, the excess being accounted for by both suicide
and premature natural death.1 Not surprisingly, this devastat-
ing condition is associated with a very high risk of suicide
attempts (4% to 30%)2 and completed suicide (4% to 13%),3,4
similar to that seen in affective disorders,5 though a recent
study suggested the rate of true suicide completion is closer to
5%.6 Given the nature of losses experienced by patients with
schizophrenia—be they real (for example, social isolation or
vocational disruptions) or perceived (that is, related to delu-
sional or referential thinking)—a sense of despair is not an
unexpected finding,7 reinforcing the observation that 50% of
individuals with schizophrenia either consider or attempt end-
ing their life.8,9 Owing to their blunted or flattening of affec-
tive response and difficulty in engaging others in
conversation, they are often perceived by others to be alien-
ated from reality, including the reality of their isolation and
losses. Such complex interplay between cultural norms and
negative symptoms may distract the clinician from maintain-
ing a high index of suspicion and completing a thorough
assessment of suicidality.10–12 In contrast to the rate found in
affective dis- orders, the sex difference in suicide rate is less
pronounced in patients with schizophrenia, and those who
attempt suicide are more likely to be successful in the attempt
and use more violent means.13–17
It is widely believed that suicide in schizophrenia is an impul-
sive act that cannot be predicted—a myth that is probably in
part related to the affective blunting and disorganized behav-
iour associated with psychosis. Unfortunately, this view may
lead to a nihilistic attitude and is not supported by
epidemiologic studies, which suggest that communication of
suicidal intent before suicide occurs at least as frequently in
patients with schizophrenia (even during acute exacerbations)
as in patients with other psychiatric conditions.18 Since almost
90% of suicides occur in individuals with a DSM-IV diagno-
sis of a major mental health disorder, and 83% of these
patients have at least one contact with a medical practitioner
within 1 year of completed suicide (more than 60% have had
contact within 1 month), physician education has been a valid
target in suicide prevention strategies.19 Physician education
has been shown to increase the detection rate and prescription
of antidepressant medication in the community, which in turn
is inversely related to suicide rates.19 While it is not known
whether the results of these interventions generalize to
patients with schizophrenia, completed suicide in schizophre-
nia has been associated with poor treatment adherence and
untreated mood, substance abuse, and psychotic disorders.
The highest risk for completed suicide occurs during or soon
after hospitalization. Active measures in the prevention of sui-
cide in schizophrenia should therefore be invested in preven-
tative strategies through education and programs focusing on
the early identification and management of depression and
suicidality in schizophrenia. As for any other psychiatric con-
dition, when significant suicidality is recognized, psychiatric
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en charge clinique comporte d’assurer la sécurité immédiate, le recours à des
techniques psychosociales pour aborder la dépression et les stresseurs psychosociaux,
une pharmacothérapie axée sur la dépression et la psychose, et une planification
adéquate du congé. La clozapine est le seul antipsychotique dont l’efficacité est
prouvée pour diminuer le comportement suicidaire dans la schizophrénie.
Conclusions : La prise en charge optimale de la suicidabilité dans la schizophrénie
comporte l’incorporation des compétences cliniques de soins classiques, la sélection
de modes psychosociaux fondés sur les besoins individuels, et une pharmacothérapie
sélective axée principalement sur les symptômes psychotiques et dépressifs.
(Can J Psychiatry 2007:52[6 Suppl 1]:59S–70S)
hospitalization is often an appropriate step in the patient’s
treatment plan. However, this disposition is not without its
drawbacks since it can mislead the clinician to a false sense of
security: the first and last weeks of hospitalization seem to be
particularly vulnerable periods for risk of completed suicide,
as are the first 6 months following discharge.15
The initial management of suicidality should therefore be
guided by a heightened index of suspicion based on the afore-
mentioned epidemiologic findings.15 The following typical
clinical case scenario of a high-risk situation serves to illus-
trate this principle.
Consider the following clinical scenario. You are clinically
responsible for a young man with a 5-year history of schizo-
phrenia and a documented history of multiple hospitalizations
over the past 6 months (“revolving door syndrome”). You
have read that this well-educated young man first experienced
psychotic symptoms in university and that he has since
dropped out of school; he has become alienated from his pre-
viously extensive social support network and lives in a local
boarding home. He is difficult to engage, tends to keep to him-
self, but shows no behavioural problems. In your brief interac-
tions with this patient you sense a deep sense of sadness and
regret for lost opportunities masked behind a somewhat
blunted affect. His paranoid delusions focus on his highly suc-
cessful siblings, whom he believes have controlled his life and
brought him to his ruin. He reassures you that he has figured
out a plan to thwart their malicious schemes but will not share
it with you for fear it will be intercepted by his family. He reas-
sures you that he has no homicidal intent toward his family
because he will not partake in their “demonic schemes.” You
also learn that he believes that he was rejected by his family
“just like all prophets” are rejected, but he reminds you that his
arrival on earth had long been predicted and that he will
“purge the earth of its evil schemes.” You note that he
becomes unusually energized as he talks of his grandiose
delusional thoughts, often laughing to himself and seeming to
be responding to auditory hallucinations. Nursing staff, who
have known this man during multiple recent admissions, reas-
sure you that “he is no problem at all” and that this is his base-
line behaviour. You adjust his antipsychotic medication and
after a few weeks you note some decline in delusional preoc-
cupation, although you continue to perceive dysphoric senti-
ments behind a mask of blunted affect. Members of your
multidisciplinary team feel he is now ready for an overnight
pass as part of the discharge planning process. You remain
discomfited by your observations, though you cannot articu-
late a valid reason to defer the leave of absence. Nonetheless,
you do not inquire about feelings of hopelessness and suicidal
thoughts or plans—you realize this omission only as you write
your progress note later in the day.
Such seemingly routine assessments potentially mask suicide
risk and, unless the patient is formally evaluated for potential
suicide risk, might contribute to the misperception of the
“impulsive” nature of suicide in schizophrenia. This is not to
suggest that one can accurately identify or predict a completed
suicide on an individual basis,20,21 but to highlight that clini-
cians may have a mistaken sense of security that has no basis
in empirical evidence. This is supported by the results of a
national survey in the United Kingdom of completed suicide
with 12 months of contact with mental health services, which
showed that mental health staff underestimated the suicide
risk at the final visit in most of the completed suicides in this
survey. The health teams involved in the index cases in this
survey also identified that in their view 22% of the deaths
could have been prevented and suicide risk could have been
decreased in at least 6% of cases through measures aimed at
improving adherence and supervision.22
Key Point: The risk of suicide and suicidal behaviour
in schizophrenia is significant and matches that of mood
disorders. The clinician needs be alert to subtle hints of
suicidality, particularly during high-risk periods. Suicide
in schizophrenia is often not as impulsive as is
commonly believed.
Since completed suicide cannot be reliably predicted in the
individual patient, what then should constitute a “red alert” in
terms of suicide risk in patients suffering from schizophrenia?
Since most clinicians are trained to assess suicidality in the
presence of a major mood disorder, such as a major depressive
episode, a mixed manic state, or even a dysphoric state reac-
tive to interpersonal conflict in persons with certain personal-
ity traits, it is critical to appreciate that in schizophrenia the
presence of depression is only one of many factors contribut-
ing to the patient’s suicidality and, if present, may be masked
by a primary negative syndrome state. In a cross-sectional
study of 290 patients suffering from a nonaffective psychosis,
Fialko and colleagues23 report a high prevalence of suicidal
ideation (41%) that was associated not only with depression,
anxiety, and alcohol consumption, as expected, but also with
negative perception of the self (for example, “I am unloved”),
others (“other people are harsh”), and their illness itself (loss
of control, indefinite course, impact on their lives). Interest-
ingly, the perception of their illness was not correlated with
positive symptoms but rather with general psychopathology,
suggesting that patients experiencing suicidal ideation may be
more likely to suffer a wider range of mental problems in addi-
tion to positive symptoms. The authors consider this finding
in light of one view that suicide may be a rational attempt to
escape from feelings of entrapment.24
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To illustrate this, consider a young woman struggling with an
internal conflict concerning delusional religious beliefs, such
as delusional guilt for which she sees only eternal damnation
and her deserving of death. She can see no way out of this life-
long curse and perceives no support in friends or family mem-
bers, whom she perceives as equally critical. She is aware of,
though cannot explain, her inability to “get up and go” or per-
form activities she was previously proficient in, and her
inability to communicate meaningfully with others further
contributes to her profound sense of isolation. This combina-
tion of what we call “symptoms” (but what our patients call
“experience”) is actually quite a typical scenario of a patient
with schizophrenia. Indeed, we may become so desensitized
to these symptoms that we hear, but fail to listen to, an intense
sense of despair masked behind a blunted dysphoric affective
tone in the narrative. In so doing, we fail to use the tool of
empathy, which is to the psychiatrist what the stethoscope and
palpating hand are to the internist. Our patients too often tell
us how “the voices are so real to me, but nobody believes me,”
that we easily become desensitized to the pain and isolation
being expressed—if we did allow ourselves to listen, we
would immediately realize how easily such an individual can
spiral down a state of suicidal despair, even in the absence of
clinical depression.
A recent cross-sectional study including a relatively small
number of patients with schizophrenia (n = 62), recently
admitted to hospital following a suicide attempt, identified 2
subgroups of suicide attempters—a subgroup primarily moti-
vated by depressive symptoms and another subgroup
motivated by psychotic symptoms.25 In contrast to the psy-
chotic subgroup, the depressive subgroup was characterized
by greater hopelessness and depression, higher educational
attainment, longer duration of illness, and past suicide
attempts. Both subgroups were characterized by the persis-
tence of hopelessness at 1-year follow-up, while low mood
persisted in the depressive subgroup. This study highlights the
importance of understanding the nature and content of the
psychotic experience, as well as the trait-like nature of low
mood and hopelessness as risk factors in the identification of
schizophrenia patients at high risk of suicidality.
The importance of the level of psychotic symptoms in
suicidality in schizophrenia was highlighted in the results of a
recent Canadian case–control study of suicide victims (n = 45)
compared with control subjects with schizophrenia who had
not completed suicide. In addition to a diagnosis of depressive
disorder not otherwise specified (NOS) and a documented
family history of suicidal behaviour, moderate-to-severe cur-
rent positive (but not negative) psychotic symptoms emerged
as an independent predictor of completed suicide.26 The pro-
tective nature of negative symptoms is consistent with previ-
ous reports,27 while the absence of correlation with
impulsive-aggressive behaviours argues against the myth of
impulsivity of the act of suicide in schizophrenia. Similarly,
cluster A and C personality traits were protective, possibly
owing to indirect effects of negative symptoms and avoidance
of social stressors.
Risk factors for suicidality in schizophrenia are best grouped
into those common to other psychiatric disorders and those
specific to schizophrenia. General risk factors for suicide in
general psychiatry include a history of impulsivity, violence,
substance abuse, low mood, lifetime suicide attempts, suicidal
plan or intent, hopelessness, perceived or real losses, poor
social support, and a history of self-injurious behaviour.28
Hawton and colleagues recently completed a systematic liter-
ature review of risk factors more specific to schizophrenia.29
Affective symptoms along with history of depression, previ-
ous attempts, substance abuse, motor restlessness, poor
adherence to treatment, fear of mental disintegration, and
recent loss were identified as major risk factors for suicide in
schizophrenia.29 Other risk factors published in the literature
include severity of hallucinations and delusional thinking,30
the first 2 years of the illness31 (though the risk persists
throughout the course of the disorder),30,32 high premorbid
socioeconomic class and high IQ,33,34 later age of onset,35
better cognitive functioning,36 revolving door syndrome,15
recent hospitalization,15 severity of parkinsonism,37 and,
albeit its role is more controversial, command auditory hallu-
cinations.30 Comorbid obsessive–compulsive disorder is
found in close to 10% of patients with schizophrenia and has
recently been associated with a higher rate of suicide attempts
in 2 studies.38,39
While mood, symptom pattern, and higher education have
been consistently shown to be risk factors in schizophrenia, a
recent study comparing these variables in 2 samples of pat-
ients with schizophrenia or schizoaffective disorder in Pitts-
burgh, Pennsylvania, and New Delhi, India, found no relation
with reported history of suicide attempts in the New Delhi
sample.40 While several social and cultural differences in the
samples may have contributed to these results (including a
greater societal taboo relating to suicide in India, which may
lead to underreporting), this study highlights the potential for
cross-cultural differences in the study of suicidality. An anal-
ysis of the transcultural differences in suicide attempters par-
ticipating in the International Suicide Prevention Trial
(InterSePT)41 consisting of subjects recruited from North
America, South America, South Africa, eastern Europe, and
western Europe, however, found no differences in clinical
variables across the 5 groups except for an earlier age at first
suicide attempt and larger number of past attempts in the
North American group.
The clinician should take all these aspects into account before
proceeding to the next stage of the management: a clinical
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judgment regarding the appropriate level of care for the indi-
vidual patient. In so doing the clinician is encouraged to
1) direct his or her attention to the patient’s level of despair,
sadness, or hopelessness, 2) review risk factors applicable to
the particular patient within the patient’s biopsychosocial
constraints, 3) develop a thorough understanding of primary
and secondary diagnoses, and 4) make an informed judgment
free from personal, sociocultural, or political bias (for exam-
ple, hospital or emergency department capacity issues or other
perceived or real pressures to discharge patients from an
emergency department).
Key Point: General risk factors for suicidality in
schizophrenia are similar to those in other conditions.
Risk factors specific to schizophrenia include recent
onset, severe positive symptoms, high IQ and
socioeconomic origins, frequent brief prior
hospitalizations, and a recent hospitalization. Despair,
sadness, or hopelessness are important warning signs and
can occur in the absence of a depressive syndrome.
Treatment Modalities
Following a thorough assessment of the patient’s suicidal
ideation or behaviour, suicide risk, and contributing primary
and secondary sources of the suicidality (for example, relapse
of psychotic symptoms with auditory hallucinations and
comorbid substance abuse), a clinical decision must be taken
regarding the appropriate milieu and level of restriction
(including inpatient or day hospital or outpatient, physical or
pharmacologic restraints if necessary, level of observation
required, and community or specialized services). While
inpatient psychiatric admission may often be the safest course
of action in the suicidal patient, suicide completion in patients
with schizophrenia during and around inpatient hospitaliza-
tion is very high.42 Other safety strategies may be necessary,
depending on the level of risk determined on assessment of the
individual case. These may include closer observation by
staff, planned accompanied therapeutic passes outside the
hospital, and close follow-up on discharge from hospital.
Within this framework, subsequent active treatment
modalities can be safely instituted and with maximalefficacy.
The principal goals of active treatment are to 1) reduce psy-
chotic and depressive symptoms, 2) alleviate demoralization
and despair, 3) instil hope, and 4) address other contributory
and comorbid psychopathology, including substance abuse
and anxiety disorders. A full range of biopsychosocial modal-
ities should be considered to reach these therapeutic goals;
indeed, hopelessness, despair, and demoralization are funda-
mental human experiences that have their origin in the inter-
personal and psychosocial domains and thus need to be
addressed within the context of an empathic therapeutic rela-
tionship and understanding the psychosocial context. This
notwithstanding, most literature has focused on pharmaco-
logic interventions, specifically, the use of clozapine and
other atypical antipsychotic drugs. In view of the relatively
low incidence of suicide and the consequently very large
numbers of patients required for systematic studies, the out-
come of these interventions in preventing completed suicide
has not been systematically addressed. Further, there are lim-
ited data on the value of combining psychosocial and pharma-
cologic approaches,43 so it may often be necessary to
generalize from the evidence derived from studies directed at
the management of affective disorders. Such extrapolations
may not necessarily apply to affective symptoms occurring in
the context of a primary psychotic disorder. Sensitively
addressing subjective distress and hopelessness may be par-
ticularly pertinent to the high-risk patient, since despair has
been identified as a significant risk factor for completed sui-
cide,44 including in patients with schizophrenia.43,45 This was
highlighted in a prospective community treatment study of a
high-risk group of 122 patients suffering from early-onset
schizophrenia or schizoaffective disorder. The authors identi-
fied a baseline measure of subjective (but not objective or
interviewer-rated) distress as predictive of completed
suicide.45
The remainder of this section focuses on modalities backed by
solid empirical evidence. The goal is to establish what has
been empirically supported and what has been standard care
even if not well-studied or supported by empirical evidence,
not to diminish the importance of other important pharmaco-
logic and psychosocial interventions. The reader is also
referred to articles on managing suicidality in affective dis-
orders for a discussion on the use of other specific
psychosocial (for example, cognitive-behavioural therapy
[CBT]) and pharmacologic (for example, antidepressants and
lithium) modalities that may have specific value in the man-
agement of primary psychotic disorders with coexisting mood
fluctuations (as in schizoaffective disorder and comorbid
depressive disorder NOS) or distorted sense of self or others
that is amenable to psychotherapeutic intervention (such as
CBT). The field of psychiatry has acquired, and continues to
acquire, a large breadth and depth of evidence on which to
base clinical decisions. Nevertheless, much of clinical prac-
tice requires us to apply our therapeutic modalities to condi-
tions or combinations of disorders for which specific evidence
is lacking. In these situations we routinely “borrow” therapeu-
tic strategies from other areas in the field to fill the gap in our
armamentarium: physicians have been doing this for centu-
ries, and there is no reason to stop, given our obligation to
relieve our patients’ suffering. The awareness of these gaps in
our knowledge is critical. The consequence of not knowing
where the specific empirical evidence stops and “borrowing”
Managing Suicidality in Schizophrenia
The Canadian Journal of Psychiatry, Vol 52, Supplement 1, June 2007  63S
begins is the misplaced belief that certain interventions
“should work.” This may lead, for example, to the use of indis-
criminate polypharmacy in cases where a focus on adjunctive
psychosocial interventions would be more sensible. Nowhere
is this problem more pertinent than in a chronic illness like
schizophrenia, where the passage of time brings with it a
greater sensitivity to the adverse effects of our interventions.
A good example illustrating the gap between empirical evi-
dence and clinical practice is the use of mood stabilizers,
including lithium, in schizophrenia and schizophrenia-like
psychoses. Notwithstanding the strong evidence for lithium’s
efficacy in bipolar disorder as well as its effect of reducing
suicidal behaviour and all-cause mortality in mood dis-
orders,46 evidence for its efficacy in psychotic disorders
(alone or in combination with an antipsychotic) is either weak
or altogether absent, even though it appears to have some ben-
efit in schizoaffective disorder.
Key Point: The goals of treatment are to reduce
psychotic and depressive symptoms and alleviate
demoralization and despair. Treatment of comorbid
conditions including substance abuse and anxiety
disorders may be critical in achieving these goals.
Careful consideration should be given to the choice of
treatment setting appropriate for the individual patient.
Awareness of the extent of existing empirical knowledge
allows the clinician to borrow other therapeutic
interventions while maintaining an open mind and keen
eye on potential adverse effects.
Psychosocial Modalities
While the greatest impact on the outcome of schizophrenia
has been derived from the institution of and the adherence to
antipsychotic drug treatment,47 an integrated approach using
several psychosocial modalities is generally regarded as stan-
dard practice in managing patients with severe psychiatric
conditions such as schizophrenia.48–50 This principle was sup-
ported by a recent 2-year randomized controlled trial (RCT)
comparing integrated biomedical and psychosocial treatment
with standard care (pharmacotherapy and case management)
in patients with recent-onset schizophrenia.51 Integrated care
was shown to result in superior overall outcome measures,
including positive and negative symptoms. One of the pri-
mary goals of psychosocial interventions in schizophrenia is
to enhance adherence with psychiatric care, and poor adher-
ence with treatment is itself associated with a risk of
suicidality.29 A recent study exploring the patterns of adher-
ence with atypical antipsychotics in Quebec and
Saskatchewan confirmed that good adherence with medica-
tion was associated with the expected reduction in hospital-
ization and also demonstrated a significant association of poor
adherence with risk of death (adjusted hazard ratio of 0.58)
and suicide (adjusted hazard ratio of 0.68) in Quebec.52
Nonetheless, the independent impact of psychosocial inter-
ventions on suicidality has not been systematically measured.
Interventions supported by some degree of consistent empiri-
cal evidence for schizophrenia include family intervention,
assertive community treatment, psychoeducation, social
skills training, and supportive employment.50 When used in
conjunction with standard care, CBT for schizophrenia is
showing promise in decreasing positive and depressive symp-
toms, while increasing insight without increasing suicidal
ideation,53,54 though this has not yet been definitively shown
to translate into improved long-term function.55 A recent
Cochrane review concluded that, while CBT is a promising
treatment modality, the current trial-based evidence does not
yet support its widespread adoption for use in clinical man-
agement of primary psychotic disorders.56 Case management,
while widely practised, is also surprisingly underevaluated
and possibly overvalued, though this may partly be a result of
the widely variant case management approaches for different
subpopulations.57 There is no indication for psychodynamic
interventions,58 and even though an understanding of the
psychodynamic theories may successfully inform beneficial
supportive therapy when combined with standard treatment,
psychodynamic therapies in schizophrenia demonstrate no
advantages over antipsychotic drug treatment alone.59
There is no literature addressing the value of these interven-
tions in the specific management of suicidality in schizophre-
nia, so the value of these approaches in suicidal patients with
schizophrenia can only be extrapolated from 1) the sparse lit-
erature and accepted expert opinion that integration of these
modalities with pharmacotherapy decreases nonadherence
and therefore improves clinical outcome48 and 2) the emerg-
ing evidence for the value of cognitive-behavioural interven-
tions for depression, hopelessness, and suicidality in the
context of primary affective disorders described elsewhere in
this compendium.
The absence of published literature on the efficacy of these
psychosocial modalities on suicidality in schizophrenia does
not exclude the possibility of an indirect effect through sev-
eral important psychosocial factors that are known to be asso-
ciated with demoralization and suicidality itself. Psychosocial
interventions would be expected to result in increased hope-
fulness, adherence to treatment, and enhanced therapeutic
alliance, which in turn may be protective (in terms of
suicidality) for the individual patient. It has been suggested
that the maintenance of family structure and enhanced adher-
ence to psychiatric follow-up may account in part for the
better outcome of schizophrenia in less-developed coun-
tries.60 Similarly, poor staff–patient relationships, poor conti-
nuity of care, and inadequate management of depression are
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key factors associated with lack of “preventability” of com-
pleted suicide.11,22
Several caveats pertain to the literature on psychosocial inter-
ventions in schizophrenia. First, these interventions are gener-
ally administered by highly trained therapists and often
involve the use of standardized manuals, a situation that is
unlikely to generalize to the community. However, a recent
study comparing CBT (administered by trained psychiatric
nurses) with standard therapy has challenged the necessity of
intensive training for the effective delivery of these therapeu-
tic modalities.53 The real-world applicability of these tech-
niques is critical if they are to have a palpable impact on the
routine care of patients suffering from primary psychotic dis-
orders. A second caveat pertains to the presence or attainment
of insight—that is, the awareness of illness, its consequences,
and need for treatment—often an explicit goal of
psychoeducation strategies. Perhaps not surprisingly, insight
may not necessarily lead to improved outcome. This was illus-
trated in one randomized controlled study that failed to find
any beneficial effects on clinical outcome of brief psycho-
education following discharge from an inpatient setting.34
Insight regarding the condition and need for treatment clearly
has positive implications for adherence with treatment, but it
has also been associated with depression and increased sui-
cidal risk in some,7,33,34,61,62 but not all,53 studies, posing a
potential therapeutic dilemma. It is not known whether the
advantages of insight in improving adherence and outcome
outweigh their potential risk for demoralization and suicidal
behaviour. Data from InterSePT have shown that, while
awareness of the illness at baseline was associated with
increased suicidality, awareness that was derived in the course
of treatment was associated with a decreased risk of suicidal
behaviour.63
How can a practising clinician apply this to his or her daily
practice? It’s much like delivering bad news in general
medicine—a patient is not to be overburdened with details on
initial diagnosis, and the clinician provides as much informa-
tion as the patient is willing and able to receive, a process in
which the physician gently leads but takes his or her cues from
the patient’s state and willingness to know more. If the patient
formulates the illness as a sleep disorder and has difficulty
focusing his or her attention despite a physician’s initial
appraisal and discussion of psychosis, then it is unlikely that
aggressive insistence on accepting a schizophrenia diagnosis
at that time is going to be of any benefit to the patient. Rather,
discussion of the medication and side effects, including
emphasis on the sedative side effect of the medicine and its
impact on reducing distractibility, may be both genuine as
well as more likely to promote adherence and therapeutic alli-
ance. This is indeed the core of the art of medicine and can
only be learnt at the bedside.
Notwithstanding these caveats, the integration of
psychosocial and pharmacotherapeutic modalities tailored to
the patient’s particular needs64 remains an integral component
in managing suicidality in schizophrenia.48,50,57 This is sup-
ported by results from a 1-year follow-up of first-episode
patients participating in a randomized controlled study com-
paring integrated treatment (consisting of antipsychotic treat-
ment, assertive community treatment, social skills training,
and psychoeducational family treatment) with standard treat-
ment (antipsychotic medication and variable family
psychoeducation).43 These data not only showed superior
effects of the integrated approach on positive and negative
symptoms but also increased patient satisfaction and signifi-
cantly decreased hopelessness in this group.43
Key Point: The efficacy of individual psychosocial
modalities on suicidality in schizophrenia has not yet
been validated, but integrating psychosocial treatments
with standard care is recommended when treating
suicidality in schizophrenia to address despair and
encourage adherence to treatment.
Pharmacologic Approaches
First-Generation Antipsychotic Drugs. The literature on the
effects of first-generation antipsychotic drugs on suicidal
behaviour has been inconsistent in determining whether these
neuroleptics have had any impact on suicidality in schizo-
phrenia.65 These inconsistencies may be related to several
methodological factors, including the (retrospective) design
of most of these studies, failure to address confounding fac-
tors, comorbidity, multiple medications, and absence of ran-
domization in treatment assignment in many of these
studies.66 No clear dose–effect relation with suicidality has
been found for neuroleptics, with studies suggesting no differ-
ences in daily neuroleptic dose in completed suicides when
compared with that in control cases,67 higher suicidality with
lower doses,68–71 and even higher suicidality at higher
doses.72,73 It has been suggested that these inconsistencies
reflect an interaction of selection bias (more severely ill
patients receiving higher doses), adverse effects
(extrapyramidal symptoms [EPS] at higher doses contributing
to increased suicide risk), and diagnosis (patients with more
mood symptoms than psychotic symptoms may have received
or tolerated lower neuroleptic doses),65 though they certainly
do not definitively exclude a small effect of neuroleptics on
suicide risk.74 Wilkinson and Bacon found a lower likelihood
of suicide attempts in patients receiving antipsychotic drugs,
even though suicide completers did not differ in their use of
antipsychotics.75 Further, in a prospective case–control study,
Johnson and colleagues found more self-injurious behaviours
following discontinuation of depot neuroleptics at 18 months
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when compared with patients who were maintained on the
medication, arguing for a protective effect of neuroleptics on
suicidal behaviour in schizophrenia.76
The early literature on suicide and schizophrenia suggests that
the advent of neuroleptic medications has done little to
decrease the suicide rate in schizophrenia (in the United
States) from preneuroleptic times.5,77 This (and the evidence
discussed above does not fully support this conclusion) sug-
gests that the etiology of suicidal behaviour in schizophrenia
is by far more complex than that of a direct relation with ill-
ness severity as described by positive symptoms (the primary
target of neuroleptics). Considering our earlier discussion of
the devastating impact of the illness beyond positive symp-
toms alone, this should not come as a surprise. Indeed, one ret-
rospective analysis of suicidality found no difference in
suicidality in responders to neuroleptics, compared with those
who were deemed treatment-resistant,78 suggesting a mecha-
nistic separation between the effects on (positive) symptoms
and those on suicidality. Prospective studies of patients with
borderline personality disorders79,80 and multiple suicide
attempts81 have suggested a specific reduction in suicidal ten-
dencies following neuroleptic treatment, implying that, if
neuroleptics have any impact on suicidality in schizophrenia,
this effect may be mediated through pathophysiologic
mechanisms other than direct intervention in the psychotic
process itself.
While the foregoing discussion should serve as a reminder
that suicide in schizophrenia is not necessarily driven by posi-
tive symptoms alone, a note of caution is warranted on the
interpretation of these data, since active illness, including
command auditory hallucinations, has been associated with
suicidality in schizophrenia in a Finnish psychological
autopsy study of suicide victims suffering from schizophre-
nia.30 Results from the same psychological autopsy study also
suggested that most suicide victims either received inade-
quate doses of antipsychotic medication or were nonadherent
to their prescribed medications.82 These data, as well as the lit-
erature discussed earlier in this article, lead us to argue that
suicidal ideation or behaviour in the context of active illness
(that is, positive symptoms) ought to continue to be taken seri-
ously, even when schizophrenia is being treated. Further, the
increased rate of suicide with the advent of antipsychotic
drugs has recently been attributed to neuroleptic-induced
akathisia and dysphoria,83 which in turn have been associated
with increased suicidal behaviour and ideation.72,84,85 This
suggests that all patients should be carefully monitored for
side effects from antipsychotic drugs, particularly in the early
titration stage, and any emerging neurologic side effects ought
to be managed aggressively.86 The best-designed prospective
study on the subject of suicide and antipsychotic management
(InterSePT),87 comparing the effects of olanzapine and
clozapine on suicidal behaviour over 2 years, showed that the
severity of parkinsonism was 1 of the 4 major factors account-
ing for most of the suicidal behaviour in this cohort.37 The
American Psychiatric Association’s practice guidelines rec-
ommend that the use of first-generation antipsychotics in indi-
viduals with suicidal behaviours be reserved for those needing
depot antipsychotic medications.48 While we have reserva-
tions about some of the negative conclusions reached with
regards to the first-generation antipsychotic drugs, and taking
into consideration the data pertaining to the second-
generation antipsychotics discussed below, we concur with
the general spirit of these recommendations—that is, that
avoidance of EPS ought to be an important consideration in
the pharmacologic management of suicidal behaviour in
schizophrenia.
Atypical Antipsychotics. The advent of second-generation
antipsychotic drugs, heralded by the front-runner and still
benchmark clozapine, brought a new sense of hope to the
management of schizophrenia. While there remained some
doubt as to the impact of the first-generation drugs on
suicidality in schizophrenia, the second-generation drugs had
the benefit of allowing direct comparison with the earlier
drugs, and these data have so far been very promising.66 In
light of the foregoing discussion and the risk-factor analysis
from the InterSePT study,37 a drug intended to treat suicidality
in schizophrenia should ideally fulfill the following criteria:
 Eliminate positive symptoms
 Enhance quality of life through improved cognitive and
social functioning
 Target affective symptoms
 Be free of extrapyramidal side effects
 Decrease substance abuse
The second-generation antipsychotic drugs fulfill these crite-
ria to varying degrees, with the best evidence available for
clozapine.66 Clozapine has emerged in both epidemiologic
and clinical studies as the front-runner in the race for empiri-
cal evidence for an effect of atypical antipsychotics on sui-
cidal behaviour. Clozapine has been shown to have a
substantial effect on attempted suicide78,88,89 and completed
suicide,78, 90–92 though clozapine’s impact on completed sui-
cide remains debatable mainly because of the large numbers
of subjects that must be included in clinical studies to detect an
effect.93,94
No prospective randomized controlled studies have been
completed comparing the effect of first- and second-
generation antipsychotic drugs on suicidality, although one
small retrospective study shows that patients attempting sui-
cide were more likely to receive first-generation antipsychotic
medication, while nonattempters were more frequently
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prescribed atypical antipsychotic drugs.88 The limitations of
such studies as retrospective design have been discussed ear-
lier. Two large metaanalyses using data from randomized,
double- blind, placebo-controlled studies of risperidone,
quetiapine, and olanzapine reported no difference in suicide
attempts or completed suicide.95,96 These data need to be inter-
preted with caution since the duration of these trials was rela-
tively brief and the subjects were carefully selected, with
patients at high risk for suicide behaviour often excluded.
There is some suggestion of a decrease in suicidal thoughts
and behaviour with olanzapine treatment, compared with
haloperidol and risperidone, though there are no systematic
data for other atypical antipsychotics.97, 98 Given the emerging
literature on the effect of certain atypical antipsychotic drugs,
including olanzapine, quetiapine, and ziprasidone, on mood
symptoms, as well as their known relative freedom from EPS
at therapeutic dosages, one might predict some degree of
decreased suicidality in patients treated with these medica-
tions, though this awaits empirical validation.65
The InterSePT study91 is the only prospective, randomized,
large-scale study that sought to explore the effect of
antipsychotic drugs on suicidal behaviour, and the methodol-
ogy addresses many of the limitations inherent to retrospec-
tive and metaanalyses of smaller-scale RCTs. Using an
open-label design, this 2-year multicentre international study
(industry-funded, primarily by Novartis Pharmaceuticals)
recruited patients with schizophrenia or schizoaffective dis-
order who were deemed at high risk for suicidal behaviour
(previous suicide attempts or current suicidal ideation) and
who were then randomized to treatment with either clozapine
300 to 900 mg (n = 479) or olanzapine 10 to 20 mg (n = 477).
Subjects were followed at the same regular intervals in both
treatment groups, and clinical ratings were performed by
blinded raters. The outcome of interest was any suicidal
behaviour that included suicide attempts or completions, hos-
pitalization to prevent suicide (type 1 event), and worsening
of suicidality from baseline according to the suicide severity
subscale of the Clinical Global Impression (CGI) scale (type 2
event). The endpoints were determined by an independent
suicide monitoring board consisting of an international team
of experts in the management of suicide behaviour who were
blinded to treatment group assignment.99 The results of the
study showed that clozapine was associated with significantly
fewer type 1 and type 2 events, even though the olanzapine
group received significantly more concurrent antidepressant
and anxiolytic medication; they suggested that, compared
with olanzapine, treatment with clozapine reduced serious
suicide attempts and hospitalizations to prevent suicide by
25% (with a remarkably low number “needed to treat,” only
12 subjects). The results of this study were accepted by the US
Food and Drug Administration (FDA) as sufficient to include
suicidal behaviour in schizophrenia as an indication for
clozapine treatment and have been used to advocate for the
inclusion of this indication in other countries.83 The Canadian
health and safety authorities have not gone as far as the FDA
to license suicide prevention in schizophrenia as an indica-
tion, but the pharmaceutical company has been given permis-
sion to include the study data in their briefings to the medical
profession.
While it has been suggested that the use of clozapine in
patients at high risk for suicide may be both life-saving as well
as cost-effective,65,100 this may not generalize to patients with
schizophrenia at lower risk for suicide, owing to clozapine’s
additional side effect burden, when compared with the effects
of other first- and second-generation antipsychotic drugs.
Indeed, one study has suggested that any beneficial effects of
clozapine on decreased mortality from suicide may be offset
by an increased mortality from cardiovascular consequences
of metabolic side effects such as obesity and diabetes.101
Treatment of Depressive Symptoms. Given the importance of
depressive symptoms, including low mood and hopelessness,
as risk factors for suicidality in schizophrenia, managing
depression needs to be at the forefront of any treatment plan
for these patients. The literature on managing depression in
schizophrenia is somewhat inconsistent and does not allow
for clear, evidence-based guidelines for the practicing
clinician. Two randomized, placebo-controlled studies using
imipramine augmentation of neuroleptics suggested that
adjunctive treatment with imipramine might be useful in
the acute and maintenance treatment of postpsychotic
depression.102,103 However, subsequent studies with selective
serotonin reuptake inhibitors have yielded inconsistent
results,104 with the only double-blind controlled study (using
sertraline) showing a large placebo effect.105 Given the pau-
city of consistent literature in this area, as well as the very high
prevalence of depression in schizophrenia, the clinician
should use clinical judgment in managing individual patients.
The initial approach needs to be directed to reversible factors,
such as abuse of and withdrawal from illicit drugs, as well as
dysphoria and akathisia secondary to antipsychotic drugs. In
the presence of significant syndromal depressive symptoms, a
trial of antidepressant at the generally recommended doses is
warranted, though there are no data to conclusively guide the
clinician in determining whether a failure of an antidepressant
trial is an indication for a switch in the antidepressant or
antipsychotic drug being used.48 In general, it has been recom-
mended that depressive symptoms in schizophrenia be tar-
geted with antidepressants only if symptoms do not subside
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after treating the psychotic symptoms with an atypical
antipsychotic.106
The clinician should also be alert to the possibility of
pharmacokinetic interactions (for example, fluvoxamine and
clozapine) as well as other potential interactions on the basis
of the known side effect profile of the drug being used (for
example, combined bupropion and clozapine increase the risk
of seizures). Further, there is no empirical evidence to guide
the duration and safety of maintaining antidepressant treat-
ment following remission of symptoms.
Electroconvulsive Therapy
Electroconvulsive therapy (ECT) remains a useful therapeutic
option in schizophrenia and schizoaffective disorder and may
have a place in managing the severe depressive symptoms that
accompany these disorders.107 An acute therapeutic benefit in
suicidal ideation occurring in the context of a concurrent
mood disorder would be clinically expected, at least in the
short term, though there are no data at this time to support this
claim. Similarly the literature does not provide supportive evi-
dence that schizoaffective disorder or mood symptoms
accompanying schizophrenia predict a response to ECT, a
belief commonly held by practising psychiatrists.48 In prac-
tice, we recommend that attention be given to a thorough dif-
ferential diagnosis and diagnostic formulation before
proceeding to ECT, especially given that depressive symp-
toms in the context of an acute psychotic relapse in schizo-
phrenia often resolve with the use of antipsychotic drugs and
that the persistence of psychotic symptoms and significant
suicidality ought to alert the clinician to the possible indica-
tion of clozapine in such patients. Similarly, secondary nega-
tive symptoms from neuroleptic treatment should be
considered, although this is less frequently an issue with the
widespread use of atypical antipsychotic drugs.
Notwithstanding the limited evidence base for ECT in schizo-
phrenia, ECT remains a therapeutic option that one should
continue to consider carefully in acutely suicidal patients with
schizophrenia in the context of comorbid mood or psychotic
symptoms that have not responded to standard pharmacologic
treatment.
Conclusion
Schizophrenia carries a very high risk of suicidality (Category
A evidence), and a heightened awareness of this risk is key to
its early detection and management (Category C). Communi-
ties with early detection programs have already been shown to
be associated with lower rates of severe suicidality, compared
with other communities offering standard care,108 even
though it may be too early to estimate the precise benefit of
these programs on suicide completion.109 Individualized
treatment plans should focus on the integration of pharmaco-
logic and psychosocial therapies (Category B). Depressive
symptoms, positive psychotic symptoms, and hopelessness
are important predictors of suicidality and should be managed
aggressively (Category B), and comorbid psychiatric condi-
tions should also be addressed (Category C). Clozapine
should be considered in patients showing significant suicidal
behaviour (Category A), though other atypical antipsychotic
drugs may be useful in patients for whom clozapine is either
contraindicated or otherwise undesirable (Category B).
Extrapyramidal side effects should be avoided in all patients,
but especially so in patients at high risk for suicide (Category
B), and the use of first-generation antipsychotic drugs in
patients with suicidal behaviour should generally be limited to
patients needing depot formulations where depot formula-
tions of second-generation antipsychotic drugs are unavail-
able (Category C).
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